Insights / Research BriefFeb 01, 2024

Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development

Rachel Glennerster, Thomas Kelly, Claire T. McMahon, Christopher M. Snyder
A universal COVID-19 vaccine that is effective against existing and future variants could provide the United States population with $1.5–$2.6 trillion more in social value than variant-specific boosters. The social value of a universal vaccine eclipses the cost of incentivizing manufacturers to develop it.